The Trump administration has been working to revive its once-promising pharmaceuticals market, and now the president wants to get it back on track.
On Wednesday, the Trump administration unveiled a list of more than a dozen new tobacco products with nicotine-containing ingredients that are now part of a larger plan to revive the once-tepid tobacco market.
The tobacco industry is eager to revive, with the promise of lower prices, and the new tobacco product, Nautilins Salt, will go up for sale at the same time as the rest of the administration’s agenda on health care.
The administration also announced a new rule that aims to reduce the cost of prescription medications by 20% in the coming years.
The FDA said the rule will help to “enable the full implementation of the Trump agenda and increase the access to high-quality, affordable medications.”
On Wednesday evening, the FDA also released a proposal that aims “to improve access to affordable prescription medications” through “a national plan to implement a national network of drugstores,” which would help make it easier for consumers to shop around for drugs.
In the long run, the new plan could lead to lower costs for both the FDA and the pharmaceutical industry, said Jonathan Farrar, a partner at the law firm Morrison & Foerster who has represented the pharmaceutical companies on health policy issues.
It’s not just about getting a better deal, Farrad said.
It’s also about making it easier and more affordable to get high-dose medications, which is a big win for consumers.
“The new plan is a really good first step,” he said.
“We’re in a position where we’re not really in the business of making things better, but it does provide a real opportunity for the industry to be successful.”
Farrar said he was impressed with the industry’s willingness to go along with the administration on this issue, and said he expects the industry will likely be more inclined to take the new proposal seriously than it was previously.
But he said it’s still too early to say how well the new initiative will be received by the broader industry.
The FDA’s proposal, which it is calling the National Network of Drugstores, is expected to be released by the end of the week, and it will likely include at least five different proposed drugstores.
But in an effort to protect the interests of the industry, the agency has declined to provide detailed details about what the proposed network would look like.
Farrad and other industry advocates believe that the proposed drugstore network will be more expensive than the network that was proposed by the Obama administration.
He said he would be surprised if it came in at much less than what the new administration wants.
“If you take a look at the plan from the Obama plan, they were proposing to do that,” he told ABC News.
“The NNDS [national network of health centers] proposal is more like a cross-country system.”
He added that even if the NNPS network comes in at less than the Obama proposal, it still represents a big step forward.
“The Trump administration is going to get this right,” he argued.
“They’re going to be very, very aggressive with the NNS.”
The National Network for the Prevention of Drug Abuse has also been in talks with the FDA about a new drugstore plan.
That plan, which was unveiled in August, is also expected to include at a minimum 10 drugstores that are owned and operated by drug companies.FARRAD said he hopes the NNP will be able to compete with the established drugstore networks in the future.
“But I think this is a great first step and it’s something that they should look at in the long term,” he added.